Skip to product information
Baseball · PSA 10
2022 Bowman Chrome Prospect Fuchsia Shimmer Refractor Roderick Arias #BCP153 /199 PSA 10
$52.19
Sale price
$52.19
Regular price
2022 Bowman Chrome Roderick Arias 1st Bowman Fuchsia Shimmer
Capture a piece of baseball history with this graded gem featuring the Yankees' rising star, Roderick Arias.
You will receive the exact card shown.
- 2022 Bowman Chrome
- Roderick Arias
- #BCP153
- 1st Bowman Fuchsia Shimmer Parallel
- Graded PSA 10
About this card
This stunning 2022 Bowman Chrome card showcases the early career of Roderick Arias, a burgeoning talent with the New York Yankees. As a 1st Bowman card, it marks an important milestone in his professional journey.
The card is part of the Fuchsia Shimmer parallel set, a visually striking addition that makes it a standout piece for collectors and fans alike. Graded PSA 10, it reflects the utmost quality, making it a coveted item for serious card enthusiasts.
Exact card details
- Brand: Bowman Chrome
- Year: 2022
- Player: Roderick Arias
- Team: New York Yankees
- Card Number: BCP153
- Parallel: Fuchsia Shimmer
- Grading: PSA 10
Condition & exact-copy disclosure
The card is sold in the pictured PSA holder with the verified label grade of 10. Review the images for the exact holder, label, and certification details. Monmouth Cards does not independently re-grade slabbed cards.
Frequently asked questions
What is the exact grade of the card?
The card is graded Gem Mint 10 by PSA.
Is this a rookie card?
Yes, this is a 1st Bowman card for Roderick Arias.
What makes this card a parallel?
This card is a Fuchsia Shimmer parallel, part of a special set with unique visual characteristics.
How will the card be shipped?
The card will be securely packaged to ensure safe delivery.
Can I return the card if I'm not satisfied?
Please refer to our return policy for details on returns and exchanges.
The details provided are verified to the best ability, ensuring transparency and accuracy. Always consult images and product specs to make an informed purchase decision.